New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (DGX), a ...
Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies. Quest Diagnostics has announced the launch of a novel ...
Hosted on MSN
Quest launches flow cytometry MRD test for myeloma
Quest Diagnostics has introduced a new flow cytometry measurable residual disease (MRD) blood test for myeloma, a cancer arising from abnormal plasma cells. The test aims to enhance ultra-sensitive ...
Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. Quest Flow ...
SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ --Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results